1349 - Long-Term Efficacy and Safety of Basivertebral Nerve Ablation for Chronic Low Back Pain: A Single-Center 5-Year Prospective Study

Friday, February 20, 2026

5:00 PM - 6:30 PM AST

Presenting Author(s)

DS

Devender Singh, PhD

Scientist
Ascension Texas Spine and Scoliosis
Austin, Texas, United States

Co-Author(s)

ET

Eeric Truumees, MD

Surgeon
Ascension
Austin, Texas, United States
MG

Matthew Geck, MD

Surgeon
Ascension
Austin, Texas, United States
JS

John Stokes, MD

Surgeon
Ascension
Austin, Texas, United States

Submitter(s)

DS

Devender Singh, PhD

Ascension Texas Spine and Scoliosis
Austin, Texas, United States

Objectives: The primary aim of this study is to evaluate the long-term clinical outcomes of patients undergoing Basivertebral nerve ablation (BVNA) for chronic low back pain (CLBP) . Specifically, we aim to assess improvements in pain and disability, the achievement of clinically significant improvements, the use of adjunctive treatments, and patient-reported functional recovery.

Design: Prospective study

Results: Mean age of our cohort was 55 years (±8.2 yr). At baseline, the mean VAS and ODI scores were 6.7±1.2 and 47.8±9.3, respectively. At 3, 4, and 5 years, mean % improvements in VAS were 60.8%, 53.6%, and 67.8%, respectively, while ODI improvements were 72.3%, 77.6%, and 74.1%. Clinically significant improvements in both ODI and VAS scores were achieved by 93.3% of patients at 3 years, 80.0% at 4 years, and 86.7% at 5 years. Medication usage was reported by 13.3% of patients at 3 and 4 years, while injection usage remained consistent at 6.7% across all follow-ups. Functional recovery, defined as resuming pre-back-pain activity levels, was reported by 80.0%, 66.7%, and 86.7% of patients at 3, 4, and 5 years, respectively. Importantly, no serious device- or procedure-related adverse events were reported throughout the study. Additionally, 100% of enrolled patients completed the 5-year follow-up, ensuring robust data collection and analysis.

Conclusions: The findings of this study demonstrate that BVNA is an effective long-term treatment for CLBP, resulting in significant reductions in pain and disability. A high percentage of patients achieved clinically significant improvements in both ODI and VAS scores, with sustained functional recovery observed over 5 years. The minimal need for adjunctive treatments and the absence of serious adverse events highlights the safety and efficacy of BVNA.